Stephen Thau

Stephen Thau

Morrison & Foerster LLP

Contact  |  View Bio  |  RSS

Latest Publications

Share:

MoFo BioMeter, Volume 4, Issue 1 - Record 2014 Biometer Shows Strong Year For Biotech

The full-year 2014 BioMeter confirms that 2014 was a banner year for biotechnology. The average BioMeter value for the entire year across all transactions reporting up-front payments and stage of development was $58.7...more

5/1/2015 - Biotechnology Emerging Growth Companies Emerging Technology Companies

MoFo BioMeter, Volume 3, Issue 4

Q3 BioMeter Shows Reemergence of Late Stage Deals - The average BioMeter value in the third quarter of 2014 was $43.7 million, an increase from the $30.4 million value in the same quarter in 2013, and a slight increase...more

10/28/2014 - Biotechnology

MoFo BioMeter - Vol. 3, Issue 3, August 2014 - Q2 Biometer Shows Strong Value In Drug Discovery Platforms

The average BioMeter value in the second quarter of 2014 jumped significantly to $143.4 million, an increase from the $15.9 million value in the first quarter. This included two blockbuster deals, the $1 billion up front paid...more

8/8/2014 - Bayer Biotechnology Merck Pfizer Pharmaceutical Prescription Drugs

MoFo BioMeter - Vol. 3, Issue 2, May 2014 - Early Stage Deals Dominant Q1: Uptick in total dealmaking activity compared with same...

The MoFo BioMeter for the first quarter of 2014 shows a decrease in average BioMeter value in a quarter dominated by early stage deals. Total dealmaking activity showed an uptick compared to the same quarter in...more

5/14/2014 - Biotechnology Pharmaceutical Technology

MoFo BioMeter - Vol. 3, Issue 1, March 2014 - Q4 and FY 2013 BioMeter Shows Rebound in Value for Late Stage Products and Strong...

The full-year 2013 BioMeter analysis shows across-the-board increases in BioMeter value, with an average of $33.9 million for all transactions, up from approximately $21.2 million in 2012. Increases occurred for each stage of...more

3/28/2014 - Pharmaceutical Prescription Drugs

MoFo BioMeter - Vol. 2, Issue 4, November 2013 - Q3 BioMeter Shows Strong Early Stage Deals

The average BioMeter value in the third quarter of 2013 was $30.4 million, an increase from the $22.2 million value in the second quarter. Like last quarter, Phase 1 and Phase 2 transactions showed very strong results, with...more

11/26/2013 - Biotechnology Pharmaceutical Prescription Drugs

MoFo BioMeter - Vol. 2, Issue 3, August 2013 - Q2 BioMeter Encouraging for Products from Early Development through Phase 2

The average BioMeter value in the second quarter of 2013 was $22.2 million, an increase from the $16.3 million value in the first quarter (excluding BMS/Rickets and AZ/Moderna), and down from $59.4 million in the first...more

8/29/2013 - Biotechnology Pharmaceutical

MoFo BioMeter - Volume 2, Issue 2: May 2013 - Flat BioMeter Value and Decline in Deal Volume are Hallmarks of Q1

The Morrison & Foerster BioMeter for the first quarter of 2013 shows a flat quarter for BioMeter value and a decline in dealmaking activity. A small number of large deals dominate an otherwise quiet quarter. In the...more

5/31/2013 - Biotechnology OTC Pharmaceutical Prescription Drugs Valuation

MoFo BioMeter - Volume 2, Issue 2: May 2013 - Flat BioMeter Value and Decline in Deal Volume are Hallmarks of Q1

The Morrison & Foerster BioMeter for the first quarter of 2013 shows a flat quarter for BioMeter value and a decline in dealmaking activity. A small number of large deals dominate an otherwise quiet quarter. In the...more

5/22/2013 - Biotechnology

MoFo BioMeter - Volume 2, Issue 1: February 2013

Phase 2 Deals Dominate Q4 and Full Year 2012 - Morrison & Foerster is pleased to release the MoFo BioMeter for the fourth quarter of 2012 and for the full year of 2012. The fourth quarter of 2012 saw an uptick in...more

2/25/2013 - Biotechnology Life Sciences

Introducing the MoFo BioMeter

Morrison & Foerster is pleased to introduce the MoFo BioMeterâ„¢, an index developed to measure the health of the biotechnology industry. BioMeter takes the pulse of the industry by looking at a key measure of deal...more

12/15/2012 - Biotechnology Life Sciences

11 Results
|
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:

Sign up to create your digest using LinkedIn*

*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.
×